New shot aims to stop catheter clots without blood thinners
NCT ID NCT07498517
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether a single dose of gruticibart, a monoclonal antibody, can prevent blood clots that often form when a central venous catheter is placed. About 90 adults getting a catheter will receive either the drug or a placebo. The goal is to see if gruticibart reduces clots and the need for risky blood thinners.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gruticibart (a monoclonal antibody)
- What this could lead to
- If it works, this could offer a way to prevent catheter-related blood clots without the bleeding risks of standard blood thinners.
- What could go wrong
- This is an early Phase 2 trial with only 90 participants, so results may not apply to everyone. The drug could still cause bleeding or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new device suck out deadly lung clots?
- Can a sedative help rebuilt tissue survive after cancer surgery?
- Your DNA could determine which heart drug works best
- Can we predict dangerous blood clots in lymphoma patients? a major study aims to find out
- Experimental biologic aims to stop recurrent clots in antiphospholipid syndrome
- New method aims to make compression stockings easier to wear